A double-blind study comparing the safety, tolerability, and efficacy of ioversol 320 and iopamidol-300 in cerebral angiography.
Ioversol is a new nonionic, triiodinated, water-soluble contrast medium. In a controlled double-blind study, ioversol 320 versus iopamidol-300 was tested on 60 patients in cerebral angiography. The safety of the contrast medium, the general and local tolerance, as well as the contrast quality were tested. In this study, ioversol 320 displayed no differences from iopamidol-300 in terms of contrast quality, neurologic status, and liver and kidney tolerance. In the local tolerance test, patients receiving ioversol 320 perceived significantly less heat than patients receiving iopamidol-300 when all injections were considered.
Ringel
K
K
Department of X-ray Diagnostics, Central Clinic Augsburg, West Germany.
Kuehn
J
J
D000328:Adult; D000368:Aged; D001831:Body Temperature / Q000187:drug effects; D002561:Cerebrovascular Disorders / Q000000981:diagnostic imaging* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D003287:Contrast Media; D004311:Double-Blind Method; D004361:Drug Tolerance; D005158:Facial Paralysis / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007463:Iodobenzoates; D007479:Iopamidol / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011859:Radiography; D012107:Research Design; D014283:Triiodobenzoic Acids / Q000633:toxicity
D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D007479:Iopamidol; C054871:ioversol